Compare SLNH & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLNH | TXMD |
|---|---|---|
| Founded | 1961 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.5M | 24.3M |
| IPO Year | 2005 | 2012 |
| Metric | SLNH | TXMD |
|---|---|---|
| Price | $1.19 | $2.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 32.8K |
| Earning Date | 05-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.41 | 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $38,021,000.00 | $1,761,000.00 |
| Revenue This Year | $55.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $106.00 |
| Revenue Growth | ★ 80.49 | 35.25 |
| 52 Week Low | $0.59 | $0.99 |
| 52 Week High | $5.14 | $2.95 |
| Indicator | SLNH | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 45.47 |
| Support Level | $1.08 | $1.95 |
| Resistance Level | $1.41 | $2.15 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 41.38 | 18.79 |
Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.